^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    podentamig (MK-4002)

    i
    Other names: MK-4002, HPN-217, BCMA TriTAC, HPN 217, HPN217, MK4002
    Company:
    Merck (MSD)
    Drug class:
    CD3 agonist, BCMA inhibitor
    Related drugs:
    1m
    Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (HPN217) (clinicaltrials.gov)
    P1, N=100, Active, not recruiting, Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial primary completion date
    |
    podentamig (MK-4002)
    3ms
    Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (HPN217) (clinicaltrials.gov)
    P1, N=100, Active, not recruiting, Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Trial completion date: May 2025 --> Nov 2025
    Trial completion date
    |
    podentamig (MK-4002)
    6ms
    A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM (clinicaltrials.gov)
    P1, N=97, Active, not recruiting, Harpoon Therapeutics | Trial completion date: Jun 2024 --> May 2025 | Trial primary completion date: Jan 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    podentamig (MK-4002)
    2years
    Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM) (ASH 2022)
    Changes in biomarkers associated with clinical responses were observed. NCT04184050
    P1 data • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD69 (CD69 Molecule)
    |
    podentamig (MK-4002)
    3years
    An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma (ASH 2021)
    Premedication to minimize cytokine release syndrome (CRS) includes dexamethasone, diphenhydramine, acetaminophen, and a proton pump inhibitor...Patients treated received a median of 8 (range of 4 – 16) prior systemic regimens, including 5 patients who received prior BCMA-targeted belantamab mafodotin or orvacabtagene autoleucel...Dose escalation, including implementation of step dosing, with the goal of establishing an RP2D regimen, is ongoing. NCT04184050
    P1/2 data • IO biomarker
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • IL10 (Interleukin 10)
    |
    dexamethasone • Blenrep (belantamab mafodotin-blmf) • podentamig (MK-4002) • orvacabtagene autoleucel (JCARH125)
    4years
    [VIRTUAL] HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma (ASH 2020)
    The study will also evaluate overall response rate (ORR) based on IMWG response criteria, progression-free survival (PFS) and overall survival (OS), duration of response (DOR), immunogenicity of HPN217, and other exploratory endpoints related to the mechanism of action of HPN217. (NCT04184050)
    Clinical • P1/2 data • PK/PD data • IO biomarker
    |
    CD38 (CD38 Molecule)
    |
    podentamig (MK-4002)